Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NETWORK × Neuroectodermal Tumors, Primitive × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

OTHER 16 INDUSTRY 8 NIH 3 NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 62 Breast Neoplasms 55 Lung Neoplasms 53 Lymphoma 47 Ovarian Neoplasms 43 Sarcoma 40 Prostatic Neoplasms 35 Leukemia 35 Multiple Myeloma 34 Central Nervous System Neoplasms 31 Head and Neck Neoplasms 28 Colorectal Neoplasms 28 Carcinoma, Ovarian Epithelial 27 Rectal Neoplasms 26 Neoplasm Metastasis 26 Squamous Cell Carcinoma of Head and Neck 25 Melanoma 25 Urinary Bladder Neoplasms 23 Precursor Cell Lymphoblastic Leukemia-Lymphoma 23 Lymphoma, Large B-Cell, Diffuse 23 Leukemia, Lymphocytic, Chronic, B-Cell 23 Brain Neoplasms 23 Uterine Cervical Neoplasms 20 Glioblastoma 20 Endometrial Neoplasms 20 Fallopian Tube Neoplasms 19 Adenocarcinoma of Lung 19 Leukemia, Myeloid, Acute 17 Gliosarcoma 17 Colonic Neoplasms 16

Interventions

Temozolomide 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02358356 2022-07-05

CONTROL NETS

Australasian Gastro-Intestinal Trials Group

Phase 2 Completed

Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡